Literature DB >> 19758589

EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation.

Peter Seizer1, Tanja Schönberger, Moritz Schött, Michael R Lang, Harald F Langer, Boris Bigalke, Björn F Krämer, Oliver Borst, Karin Daub, Olaf Heidenreich, Roland Schmidt, Stephan Lindemann, Yared Herouy, Meinrad Gawaz, Andreas E May.   

Abstract

UNLABELLED: Upon coincubation with platelets, CD34(+) progenitor cells have the potential to differentiate into foam cells, and thereby may promote the progression of atherosclerosis. The exact mechanism of MMP-regulation during the cellular differentiation process to foam cells is still unclear. Thus, we investigated the role of EMMPRIN (CD147) and its ligand cyclophilin A (CyPA) during foam cell formation originating from both monocytes/macrophages and CD34(+) progenitor cells. METHODS AND
RESULTS: Differentiation of CD34(+) progenitor to foam cells was analyzed in a coculture model of progenitor cells and platelets. While CD34(+) cells did not express EMMPRIN or MT1-MMP, mature foam cells strongly expressed EMMPRIN, which was associated with MT1-MMP expression as well as MMP-9. Gene silencing of EMMPRIN by siRNA during the cell differentiation process hindered not only the upregulation of MMPs (MT1-MMP, MMP-9), but also the secretion of the cytokine M-CSF. During the differentiation process CyPA was substantially released into the supernatant. The presence of the CyPA inhibitor NIM811 significantly reduced MMP-9 secretion during the differentiation process. Similar results were obtained using the classical pathway of foam cell formation by coincubating human macrophages with AcLDL. Additionally, the presence of soluble EMMPRIN ligands (CyPA, recombinant EMMPRIN) further enhanced MMP-9 secretion by mature foam cells. Consistently, CyPA and EMMPRIN were found in atherosclerotic plaques of ApoE-deficient mice by immunohistochemistry.
CONCLUSION: EMMPRIN is upregulated during the differentiation process from CD34(+) progenitor cells to foam cells, whereas its ligand, CyPA, is released. The CyPA/EMMPRIN activation pathway may play a relevant role in promoting the vulnerability of atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758589     DOI: 10.1016/j.atherosclerosis.2009.08.029

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  39 in total

Review 1.  Proteotoxic stress and circulating cell stress proteins in the cardiovascular diseases.

Authors:  Brian Henderson; A Graham Pockley
Journal:  Cell Stress Chaperones       Date:  2012-01-05       Impact factor: 3.667

2.  Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion.

Authors:  Peter Seizer; Carmen Ochmann; Tanja Schönberger; Sebastian Zach; Melanie Rose; Oliver Borst; Karin Klingel; Reinhard Kandolf; H Robson MacDonald; Romana A Nowak; Stefan Engelhardt; Florian Lang; Meinrad Gawaz; Andreas E May
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

Review 3.  Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases.

Authors:  Chao Xue; Mark P Sowden; Bradford C Berk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-03-29       Impact factor: 8.311

4.  Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9.

Authors:  Mingjun Zhang; Chun Dai; Hengrui Zhu; Shuai Chen; Yanhua Wu; Qiang Li; Xianzhuo Zeng; Wenzhang Wang; Jie Zuo; Mei Zhou; Zongjun Xia; Guoqing Ji; Hexige Saiyin; Lunxiu Qin; Long Yu
Journal:  Mol Cell Biochem       Date:  2011-06-11       Impact factor: 3.396

5.  Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.

Authors:  Sumalee Obchoei; Kanlayanee Sawanyawisuth; Chaisiri Wongkham; Watchara Kasinrerk; Qizhi Yao; Changyi Chen; Sopit Wongkham
Journal:  Tumour Biol       Date:  2014-10-10

Review 6.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

7.  PPIA rs6850: A > G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery disease.

Authors:  A Vinitha; V Raman Kutty; A Vivekanand; G Reshmi; G Divya; S Sumi; K R Santosh; N S Pratapachandran; Mullassari S Ajit; C C Kartha; Surya Ramachandran
Journal:  Mol Cell Biochem       Date:  2015-12-24       Impact factor: 3.396

8.  Extracellular Cyclophilin A Augments Platelet-Dependent Thrombosis and Thromboinflammation.

Authors:  Saskia N I von Ungern-Sternberg; Sebastian Vogel; Britta Walker-Allgaier; Sascha Geue; Andreas Maurer; Anna-Maria Wild; Patrick Münzer; Madhumita Chatterjee; David Heinzmann; Elisabeth Kremmer; Oliver Borst; Patricia Loughran; Alma Zernecke; Matthew D Neal; Timothy R Billiar; Meinrad Gawaz; Peter Seizer
Journal:  Thromb Haemost       Date:  2017-11-30       Impact factor: 5.249

9.  Differential MMP-9 activity in CD34⁺progenitor cell-derived foam cells from diabetic and normoglycemic patients.

Authors:  J U Schmohl; K Daub; S N I von Ungern-Sternberg; S Lindemann; T Schönberger; T Geisler; M Gawaz; P Seizer
Journal:  Herz       Date:  2013-12-05       Impact factor: 1.443

10.  Functions of cyclophilin A in atherosclerosis.

Authors:  Zhang Tian-Tian; Zhang Jun-Feng; Ge Heng
Journal:  Exp Clin Cardiol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.